Entasis Therapeutics Announces Oral and Poster Presentations of its Pathogen-Targeted Antibiotic Clinical Programs at ASM Microbe 2019
June 10, 2019 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
DNV GL Healthcare Focuses on Overcoming Antimicrobial Resistance in Nation's Hospitals
May 29, 2019 16:27 ET
|
DNV GL Business Assurance USA, Inc.
MILFORD, OHIO, May 29, 2019 (GLOBE NEWSWIRE) -- As the Centers for Disease Control and Prevention (CDC) ramps up the nation’s attempts to neutralize antibiotic/anti-microbial resistance (AMR) in...
Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019 16:00 ET
|
Melinta Therapeutics
~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million, Year-Over-Year ~ ~...
Entasis Therapeutics Strengthens Leadership Team with Appointment of Eric Kimble as Chief Commercial Officer
April 23, 2019 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 08, 2019 07:30 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections
April 04, 2019 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious...
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
March 18, 2019 11:00 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN)...
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
March 14, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at...
Streetwise Reports Examines Small-Cap Firm Whose Livestock Feed Antibiotic Replacement Enters Large US Market
March 13, 2019 07:00 ET
|
Streetwise Reports Llc
SAN FRANCISCO, March 13, 2019 (GLOBE NEWSWIRE) -- Canada-based Avivagen Inc.'s (VIV:TSX.V) proprietary OxC-beta™ Livestock premix for livestock feeds is a non-antibiotic means of maintaining optimal...
Leading-Edge Microbiome Discovery Platform Receives New Funding
February 25, 2019 09:17 ET
|
Phase Genomics
SEATTLE, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Phase Genomics, the leader in proximity ligation-based genomic solutions, announced today a year-long grant awarded by the Bill & Melinda Gates...